Holen Sie sich die Stockscreener-App
20.01
0.25%
-0.05
Handel nachbörslich:
20.20
0.19
+0.95%
Schlusskurs vom Vortag:
$20.06
Offen:
$19.72
24-Stunden-Volumen:
744.60K
Relative Volume:
0.50
Marktkapitalisierung:
$175.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.7771
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
-13.00%
1M Leistung:
-30.06%
6M Leistung:
+23.90%
1J Leistung:
+33.40%
1-Tages-Spanne:
$19.28
$20.69
1-Wochen-Bereich:
$19.28
$23.25
52-Wochen-Spanne:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
20.01 | 175.84M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix CEO presents anti-CD154 antibody research at Japan transplant congress - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Highlights Advancements in Transpla - GuruFocus
How Tonix Pharmaceuticals Holding Corp. stock performs after earningsJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Tonix Pharmaceuticals Presented an Update on Fc-modified - GlobeNewswire
Phase 1 safety & biomarker data lead Tonix's TNX-1500 toward Phase 2 for kidney transplant prevention - Stock Titan
Using portfolio simulators with Tonix Pharmaceuticals Holding Corp. included2025 Bull vs Bear & Growth Focused Entry Point Reports - newser.com
How to recover losses in Tonix Pharmaceuticals Holding Corp. stock2025 Support & Resistance & Low Risk High Reward Trade Ideas - newser.com
Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
Tonix Pharmaceuticals Holding Corp. stock retracement – recovery analysisWeekly Trade Review & AI Forecast Swing Trade Picks - newser.com
Backtesting results for Tonix Pharmaceuticals Holding Corp. trading strategiesWeekly Market Outlook & Daily Profit Focused Screening - newser.com
Analyzing Tonix Pharmaceuticals Holding Corp. with risk reward ratio chartsJuly 2025 Breakouts & Smart Money Movement Tracker - newser.com
Tonix Pharmaceuticals Holding Corp. stock daily chart insightsJuly 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat
Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK - Barchart.com
Fibromyalgia Market Expected to Gain Momentum Through 2034, - openPR.com
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 - The Manila Times
Single‑Dose TNX-801 Mpox Vaccine: Tonix to Present Safety & Durability Data at World Vaccine Congress Europe - Stock Titan
Detecting price anomalies in Tonix Pharmaceuticals Holding Corp. with AI2025 Sector Review & Real-Time Buy Signal Notifications - newser.com
Automated trading signals detected on Tonix Pharmaceuticals Holding Corp.Earnings Miss & Daily Volume Surge Trade Alerts - newser.com
What analysts say about Tonix Pharmaceuticals Holding Corp stockResistance Breakout Alerts & Affordable Growth Strategies - earlytimes.in
Tonix Pharmaceuticals (TNXP) Plans New Phase 2 Trials for Key Tr - GuruFocus
Tonix Pharma Plans Phase 2 Trial for 2026 - TipRanks
Tonix to advance cyclobenzaprine into phase 2 for depression - Seeking Alpha
Is Tonix Pharmaceuticals Holding Corp. trending in predictive chart models2025 Investor Takeaways & Daily Price Action Insights - newser.com
Custom watchlist performance reports with Tonix Pharmaceuticals Holding Corp.2025 Valuation Update & Safe Capital Growth Tips - newser.com
What data driven models say about Tonix Pharmaceuticals Holding Corp.’s futureWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Tonix Pharmaceuticals advances TNX-2900 into Phase 2 trial for Prader-Willi Syndrome - Proactive financial news
Tonix Pharma Appoints New Head of Market Access - MSN
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access - Sahm
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access By Investing.com - Investing.com Nigeria
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome to Phase 2 Clinical Trial - citybuzz
Tonix Pharmaceuticals Further Strengthens Commercial - GlobeNewswire
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access - citybiz
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain? - PharmaVoice
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access - Investing.com
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access Ahead of Tonmya™ Launch for Fibromyalgia Treatment - Quiver Quantitative
First New Fibromyalgia Treatment in 15 Years: Tonix Pharma Builds Launch Team for FDA-Approved Tonmya - Stock Titan
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):